

CORRECTION

Open Access



Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Honghong Zou[†], Baoqin Zhou[†] and Gaosi Xu^{*}

Correction to: *Cardiovasc Diabetol* (2017) 16:65

<https://doi.org/10.1186/s12933-017-0547-1>

Following publication of the original article [1] the authors reported that the first affiliation (“Medical Center of the Graduate School, Nanchang University, China”) had been added in error, and that the correct author information is as given in this erratum.

The original article can be found online at <https://doi.org/10.1186/s12933-017-0547-1>.

Received: 19 February 2018 Accepted: 19 February 2018

Published online: 09 March 2018

Reference

1. Zou H, Zhou B, Gaosi X. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. *Cardiovasc Diabetol*. 2017;16:65. <https://doi.org/10.1186/s12933-017-0547-1>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Correspondence: gaosixu@163.com

[†]Honghong Zou and Baoqin Zhou contributed equally to this work
Department of Nephrology, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Donghu District, Nanchang Zip Code: 330006, People's Republic of China